Dr. Tagawa on CTCs in Neuroendocrine Prostate Cancer

Scott T. Tagawa, MD
Published: Friday, Apr 11, 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.

In prostate cancer, there has been a problem with molecular characterization because it was traditionally difficult to biopsy bone. By counting and analyzing CTCs, physicians can characterize the disease, Tagawa says.

CellSearch, the platform that captures and counts CTCs, is generic and does not rely on a specific protein or antigen. Less is known about the neuroendocrine subset of prostate cancers because it only exists in about 25% of prostate cancer patients, Tagawa says. A study captured CTCs in neuroendocrine patients and characterized them. Tagawa says this study, although small, proves that CTCs have utility in this subset of patients.

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.

In prostate cancer, there has been a problem with molecular characterization because it was traditionally difficult to biopsy bone. By counting and analyzing CTCs, physicians can characterize the disease, Tagawa says.

CellSearch, the platform that captures and counts CTCs, is generic and does not rely on a specific protein or antigen. Less is known about the neuroendocrine subset of prostate cancers because it only exists in about 25% of prostate cancer patients, Tagawa says. A study captured CTCs in neuroendocrine patients and characterized them. Tagawa says this study, although small, proves that CTCs have utility in this subset of patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x